Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Kirby Daniel Gordon, holds the title of Chief Commercial Officer at IOVANCE BIOTHERAPEUTICS, INC..
On 2026-08-10, the insider transacted 12,437 shares.The shares were transacted at a weighted average price of $1.25 per share, resulting in a total market-relevant value of $16K.
Kirby Daniel Gordon (Chief Commercial Officer) had withheld for taxes $16K of $IOVA
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.